{"entity":{"id":"nct00438984","kind":"trial","name":"CD8+ antigen-specific T-cell clones after cyclophosphamide, with aldesleukin, in stage IV melanoma (Fred Hutchinson phase 1, NCI-2010-01280)","aka":[],"tldr":"A Seattle trial in 11 people with advanced melanoma that gave cyclophosphamide before their own melanoma-targeting T cells, followed by the immune signal IL-2. It ran from 2006 to 2012.","summary":"The registry describes a phase I study of autologous CD8+ antigen-specific T-cell clones following cyclophosphamide conditioning, with aldesleukin, in metastatic melanoma, started in December 2006, with primary completion in January 2011, completion in February 2012 and an actual enrolment of 11 (ClinicalTrials.gov NCT00438984). Cassian Yee is listed as principal investigator; the record names NIH grant R21CA128283 (ClinicalTrials.gov NCT00438984). No results are posted.","status":"completed","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT00438984","url":"https://clinicaltrials.gov/study/NCT00438984"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","aldesleukin"],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT00438984","phase":"1","setting":"Stage IV or recurrent melanoma: cyclophosphamide conditioning, then autologous CD8+ antigen-specific T-cell clones and aldesleukin","sponsor":"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, with the National Cancer Institute","result":"No results posted on ClinicalTrials.gov.","started":"2006-12","startedType":"actual","enrolled":11,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00438984/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}